Cooper Companies (NASDAQ:COO) Price Target Raised to $101.00

Cooper Companies (NASDAQ:COO) had its price objective raised by Needham & Company LLC from $99.00 to $101.00 in a research note released on Friday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the medical device company’s stock.

Several other analysts also recently weighed in on COO. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. Barclays set a $98.00 price target on shares of Cooper Companies and gave the company an “overweight” rating in a research note on Monday, January 26th. Mizuho set a $100.00 price target on Cooper Companies and gave the company an “outperform” rating in a report on Friday, December 5th. JPMorgan Chase & Co. boosted their price objective on Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. Finally, Wells Fargo & Company increased their price objective on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cooper Companies has an average rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $76.55 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.34 and a quick ratio of 0.79. The firm has a market capitalization of $14.94 billion, a PE ratio of 37.90, a P/E/G ratio of 2.13 and a beta of 1.02. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $89.83. The business’s fifty day moving average price is $82.11 and its two-hundred day moving average price is $76.00.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.07. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. On average, research analysts expect that Cooper Companies will post 3.98 EPS for the current year.

Insider Activity at Cooper Companies

In related news, insider Holly R. Sheffield acquired 1,230 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was acquired at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the acquisition, the insider directly owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. The trade was a 3.25% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Cynthia L. Lucchese acquired 1,784 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $84.06 per share, for a total transaction of $149,963.04. Following the purchase, the director directly owned 9,445 shares of the company’s stock, valued at approximately $793,946.70. This trade represents a 23.29% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 16,014 shares of company stock worth $1,304,416 in the last three months. Insiders own 2.08% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors have recently added to or reduced their stakes in the company. Root Financial Partners LLC raised its stake in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares in the last quarter. Bell Investment Advisors Inc boosted its stake in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after buying an additional 219 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new position in Cooper Companies during the second quarter worth about $36,000. True Wealth Design LLC grew its holdings in Cooper Companies by 484.8% during the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock worth $38,000 after acquiring an additional 383 shares during the period. Finally, Cromwell Holdings LLC raised its position in Cooper Companies by 128.8% in the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock worth $40,000 after acquiring an additional 273 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.